Skip to Main Content

Paper Details

Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor.
Neuro Oncol
6
2023
AT/, AT/RT, Alisertib, Aurora kinase A, Neutropenia, Patients, RT, alisertib, atypical teratoid/rhabdoid tumor, children, participants, patients, pediatric malignancy
Author NameAffiliation
Brent A OrrSt. Jude Children's Research Hospital
Ruth G TatevossianSt. Jude Children's Research Hospital
Holly LindsayTexas Children's Cancer Center, Baylor College of Medicine
Holly LindsayTexas Children's Cancer Center, Baylor College of Medicine
Lindsay KilburnChildren's National Medical Center
Lindsay KilburnChildren's National Medical Center
Patricia BaxterTexas Children's Cancer Center, Baylor College of Medicine
Amy SmithArnold Palmer Hospital for Children
Amy SmithArnold Palmer Hospital for Children
John R CrawfordUniversity of California, San Diego and Rady Children's Hospital
John R CrawfordUniversity of California, San Diego and Rady Children's Hospital
Sonia PartapStanford University
Sonia PartapStanford University
Anne Bendel
Kim E NicholsSt. Jude Children's Research Hospital
David W EllisonSt. Jude Children's Research Hospital
Giles W RobinsonSt. Jude Children's Research Hospital
Giles W RobinsonSt. Jude Children's Research Hospital
Alberto BroniscerChildren's Hospital of Pittsburgh
Amar GajjarSt. Jude Children's Research Hospital
Amar GajjarSt. Jude Children's Research Hospital
  • 1 - 21

Datasets

Release 1.2